Concizumab
Haemophilia B With Inhibitors
Novo Nordisk A/Smonoclonal_antibodyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the Haemophilia B With Inhibitors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Factor Ix CSL Behring | Phase 4 | A |
Eptacog Alfa AryoGen Pharmed Co. | Phase 4 | A |
Benefix Pfizer | Phase 4 | A |
Nonacog Beta Pegol Novo Nordisk A/S | Phase 3 | A |
Factor Ix CSL Behring | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Concizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →